age 1 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEGA - SEdation versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke 
– a Randomized Comparative Effectiveness Trial.  
 
[STUDY_ID_REMOVED]  
 
Version Date: 02/03/2021  
  
age 1 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
SEGA CLINICAL TRIAL PROTOCOL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17-0436  PROTOCOL 
NUMBER   
HSC -MS-17-0436  
PROTOCOL TITLE  SEGA - SEdation versus General Anesthesia for Endovascular Therapy in Acute 
Ischemic Stroke – a Randomized Comparative Effectiveness Trial.  
VERSION / DATE  1.8 January 8, 2021  
AMENDMENTS / 
DATE   
- / - 
 
SPONSOR  McGovern Medical School at The University of Texas Health Science Center at 
Houston (UTHealth), Department of Neurosurgery (Weatherhead Foundation)  
 STUDY CHAIR  STUDY Co -CHAIR  
 Peng Roc Chen, MD 
Associate Professor 
Department of Neur osurgery  
McGovern Medical School at UTHealth 
||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||  Andrew Barreto, MD MS 
Associate Professor 
Department of Neurology  
McG overn Medical School at UTHealth |||||| 
||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
 
STUDY Co -CHAIR  UTH SITE PI  
 
 
STEERING 
COMMITTEE  Carlos A. Artime, MD 
Associ ate Professor 
Department of Anesthesiology  
McGovern Medical School at UTHealth 
||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||| | Sunil A. Sheth, MD 
Assistant Professor 
Department of Neurology  
McGovern Medical School at UTHealth |||||| 
||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||| | 
  
STATISTICIAN   
COMMITTEE MEMBER  
 Claudia Pedroza, PhD  
Associate Professor  
Center for Clinical Research and Evidence - 
Based Medicine, McGovern Medical School 
at UT Health  
||||||||||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||||||||||||| | Sean I. Savitz, MD  
Professor  
Department of Neurology  
McGovern Medical School at UTHealth 
||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||| | 
||||||||||||||||||||||| | 
||||||||||||||||||||||||||||||||||||||||||||||||| | 
IRB NUMBER:  HSC -MS- 
 
age 1 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 PROTOCOL SYNOPSIS  
 
 
Title  SEGA : Sedation versus General Anesthesia for Endovascular Therapy in Acute Ischemic 
Stroke – a Randomized Comparative Effectiveness Tria l. 
 
 
 
 
 
 
Study Purpose   
Background : Endovascular therapy (EVT) with stent retrievers improve functional outcome 
in acute stroke patients. Although both are routinely performed as usual care during EVT, 
controversy remains regarding the optimal type of ane sthesia during EVT – general anesthesia 
(GA) vs. sedation (CS). Retrospective case -control studies found an association between better 
clinical outcomes with the latter. However, one small, single -center randomized trial 
suggested no significant difference s in early  outcomes.  
 
Primary Objective : To estimate overall treatment benefit (improvement in disability) among 
acute ischemic stroke patients that are randomized to GA compared with CS during 
endovascular therapy.  
 
Secondary Objectives : Assess safety (as  measured by incidence of symptomatic intracranial 
hemorrhage); rates of EVT procedural complications, reperfusion; and quality of life.  
 
Design  Multicenter, randomized, comparative effectiveness trial with un -blinded caregivers but 
blinded assessors (PRO BE – Prospective Randomized Outcome Blinded Endpoint).  
 
Study Population 
Overview  260 total acute ischemic stroke patients with proximal intracranial arterial occlusions treated 
with endovascular therapy within 16 hours of symptom onset. Patients must not  require 
intubation for any clinical indication. Arterial occlusion must be demonstrated by either CT - 
angiogram (CTA) or MR -angiogram (MRA).  
 
 
Intervention  Time of randomization is study time=0. Patients will be randomized 1:1 to receive during 
endovascu lar therapy either:  
1) General anesthesia (balanced for equal randomization into intravenous vs. inhalational) 
or 
2) Sedation  
Both GA and CS delivered and managed by anesthesiologist.  
 
Primary Outcome  Independent functional outcome as measured by the modified o rdinal Rankin Scale (mRS) at 
90 days assessed by study personnel blinded to treatment.  
 
 
 
 
Secondary 
Outcomes  1) Dichotomized mRS at 90 days (0 -2 vs 3-6) 
2) Safety as measured by rates of symptomatic intracerebral hemorrhage within 24 -36 hours 
after endovascula r therapy.  
3) Angiographic reperfusion defined as modified TICI score ≥  2b. 
4) Peri-procedural  complications.  
5) Difference in 24 -36-hour NIHSS  scale.  
6) Proportion of independent functional outcome at 90 days in GA patients treated with 
inhalational vs. intravenous  medications.  
7) Difference in quality of life at  90-days.  
IRB NUMBER: HSC -MS-17-0436  
age 1 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
 
 
Study Duration  Total trial duration: 24 ± 4 months  
a. Enrollment – approximately 18 months with 6 months of data -monitoring and statistical 
analysis  
b. Patient participation - 90 days 
 
 
 
 
Statistics   
• Planned number of sites (US + international):  10-15. 
• Sample size: 260 patients randomized 1:1 (130 per  group).  
• Final analysis uses a Bayesian approach to obtain odds ratio (OR) of good functional 
outcome at 90 -days. Bayesian prior assumes tr eatment equipoise and uses a neutral, 
informative prior (OR=1.0; 95% credible intervals of  0.3-3.0). 
• Trial success is defined as a >80% posterior probability that GA is superior (OR >1.0 of 90 - 
day mRS) to CS.  
 
 
 
 
 
 
Assessments   
• Baseline : History & physic al exam; vital signs; laboratory tests; non -contrast CT head, 
arterial vessel imaging – CTA or MRA, NIHSS, pre -stroke mRS, home  medications.  
• Endovascular Procedure : Continuous vital signs (Blood pressure, pulse, oxygen 
saturation, PETCO 2 in general anesthe sia [GA] patients);anesthesia medications; monitor 
for device -specific malfunction and serious adverse events; cross -over (e.g., CS to  GA).  
• 24-36 hours post EVT : Non-contrast head CT or MRI brain as per local usual care; 
NIHSS  
• 7-days or discharge (whicheve r occurs first) : Vital signs, physical examination,  mRS, 
NIHSS, Blinded assessment of mRS and NIHSS; Stroke  etiology.  
• 90 ± 15 days : Blinded assessment of mRS and Quality of Life; Stroke  etiology.  
 
Significance  Data generated will inform the optimal anesth esia management of EVT -treated ischemic 
stroke patients and would be expected to result in significant change of medical practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IRB NUMBER: HSC -MS-17-0436  
…………………  
 
age 4 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 TABLE OF CONTENTS  
LIST  OF ABBREVIATIONS  ................................ ................................ ................................ ................................ ................................ . 5 
1.0 BACKGROU ND AND  RATIONALE  ................................ ................................ ................................ ................................ ..............  7 
1.1 RETROSPECTIVE STUDIES OF ANESTHESIA DURING  ENDOVASCULAR THERAPY  ................................ ................................ ................................ .. 7 
1.2 RANDOMIZED TRIALS OF CONSCIOUS SEDATION VS . GENERAL ANESTHESIA DURING  ENDOVASCULAR  THERAPY  ................................ .... 7 
2.0 STUDY  OBJECTIVES  ................................ ................................ ................................ ................................ ................................ .... 10 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ ................................ ................................ .............  10 
2.2 SECONDARY  OBJECTIVES  ................................ ................................ ................................ ................................ ................................ ................................ ..... 10 
3.0 STUDY  ENDPOINTS  ................................ ................................ ................................ ................................ ................................ ...... 10 
3.1 PRIMARY  ENDPOINT  ................................ ................................ ................................ ................................ ................................ ................................ ...............  10 
3.2 SECONDARY  CLINICAL ENDPOINTS  ................................ ................................ ................................ ................................ ................................ ...................  10 
3.3 SECONDARY  SAFETY  ENDPOINTS  ................................ ................................ ................................ ................................ ................................ ......................  10 
3.4 EXPLORATORY  ANALYSES  ................................ ................................ ................................ ................................ ................................ ................................ ... 11 
4.0 STUDY  DESIGN  ................................ ................................ ................................ ................................ ................................ ..............  11 
4.1 OVERVIEW  ................................ ................................ ................................ ................................ ................................ ................................ ................................ . 11 
4.2 ENROLLMENT  AND  RANDOMIZATION  ................................ ................................ ................................ ................................ ................................ ...............  11 
5.0 STUDY  POPULATION  ................................ ................................ ................................ ................................ ................................ .. 12 
5.1 INCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ................................ ................................ .............  12 
5.2 EXCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ................................ ................................ ............  12 
5.3 CROSSOVER  CRITERIA  ................................ ................................ ................................ ................................ ................................ ................................ ...........  13 
5.4 NPO STATUS  ................................ ................................ ................................ ................................ ................................ ................................ . 18 
6.0 STUDY  PROCEDURES ................................ ................................ ................................ ................................ ................................ .. 14 
6.1 INFORMED  CONSENT  ................................ ................................ ................................ ................................ ................................ ................................ ..............  14 
6.2 TREATMENT PERIOD  ................................ ................................ ................................ ................................ ................................ ................................ ..............  15 
6.2.1 Endovascular Proced ure and  Time  Metrics  ................................ ................................ ................................ ...........................  15 
6.2.2 Angiographic measures of arterial perfusion  and collaterals  ................................ ................................ ................................  16 
6.3 90-DAY (± 15  DAYS ) FOLLOW -UP................................ ................................ ................................ ................................ ................................ .......................  17 
7.0 ANESTHETIC  PROTOCOL  ................................ ................................ ................................ ................................ ..........................  16 
7.1 SEDATION  ................................ ................................ ................................ ................................ ................................ ................................ ................................ .. 16 
7.2 GENERAL  ANESTHESIA  ................................ ................................ ................................ ................................ ................................ ................................ ..........  18 
7.3 BLOOD  PRESSURE  MANAGEMENT  ................................ ................................ ................................ ................................ ................................ .......................  18 
7.4 ANESTHESIA  MONITORING  ................................ ................................ ................................ ................................ ................................ ................................ ... 18 
7.5 ANESTHETIC  DATA  COLLECTION  ................................ ................................ ................................ ................................ .............................  19 
8.0 SAFE TY ................................ ................................ ................................ ................................ ................................ ............................  19 
8.1 ADVERSE  EVENTS  ................................ ................................ ................................ ................................ ................................ ................................ ...................  19 
8.2 SERIOUS ADVERSE  EVENTS  (SAE S) ................................ ................................ ................................ ................................ ...............  20 
8.2.1 Reporting of Serious  Adverse Events  ................................ ................................ ................................ ................................ ..... 20 
8.3 FOLLOW -UP OF  ADVERSE  EVENTS  ................................ ................................ ................................ ................................ ................................ ....................  20 
9.0 STATISTICAL  METHODS  ................................ ................................ ................................ ................................ ...........................  21 
9.1 SAMPLE  SIZE JUSTIFICATION  ................................ ................................ ................................ ................................ ................................ ...............................  21 
9.2 STATISTICAL  ANALYSES  ................................ ................................ ................................ ................................ ................................ ................................ ....... 21 
9.3 MISSING  DATA  ................................ ................................ ................................ ................................ ................................ ................................ .........................  22 
10.0 DATA  MANAGEMEN T ................................ ................................ ................................ ................................ ...............................  22 
10.1 DATA  COLLECTION  ................................ ................................ ................................ ................................ ................................ ................................ ..............  22 
11.0 STUDY COMMITTEES AND  CORE  LABS  ................................ ................................ ................................ ..............................  23 
11.1 STEERING  COMMITTEE  ................................ ................................ ................................ ................................ ................................ ................................ ........  23 
11.2 DATA SAFETY  MONITORING  COMMITTEE  ................................ ................................ ................................ ................................ ................................ .... 23 
11.3 IMAGING  CORE  LABS  ................................ ................................ ................................ ................................ ................................ ................................ ...........  23 
12.0  REFERENCES  ................................ ................................ ................................ ................................ ................................ .............  25 
13.0 APPENDICES  ................................ ................................ ................................ ................................ ................................ ................  27 
APPENDIX I.   R ICHMOND AGITATION SEDATION SCALE  (RASS ) ................................ ................................ ................................ ................................ ..... 28 
APPENDIX II.   M ONTE CARLO SIMULATION RESULTS OF  BAYESIAN POWER  ................................ ................................ ................................ ................................ ................  29 
APPENDIX III  NPO GUIDELINES …………..…………………….……………………………  …IR…B…N…UM…B…E…R…: H…S…C-…M…S-…17…-0.34136 
age 5 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
List of Abbreviations  
 
A1 1st segment of anterior cerebr al artery  
A2 2nd segment of anterior cerebral  artery  
ACA  Anterior Cerebral  Artery  
AE Adverse  event  
AHA  American Heart Association 
A-line or Aline  Arterial  Line 
ASA  American Stroke  Association  
aICH  Asymptomatic intracerebral  hemorrhage  
aPTT  Activated partia l thromboplastin  time 
aOR Adjusted Odds  Ratio  
aRR Adjusted Relative  Risk 
ASPECTS  Alberta Stroke Program Early CT Score 
BA Basilar  Artery  
BP Blood  Pressure  
CABG  Coronary artery bypass  graft 
CAS  Carotid Artery  Stenting  
CBC  Complete blood  count  
CEA  Carotid  Endarterectomy  
CFR  Code of Federal  Regulations  
CI Confidence  interval  
CK Creatine kinase  
CrCl  Creatinine  clearance  
CrI Credible  Interval  
CO 2 Carbon dioxide  
CRF  Case Report  Form  
CS Conscious  Sedation  
CT Computed tomography  
CTA  Computed tomography -Angiogram  
CTP Computed tomography -Perfusion  
CVA  Cerebrovascular  accident  
DBP  Diastolic blood  pressure  
DTN  Door to  needle  
DTG  Door to  groin  
ECG  Electrocardiogram  
EDH  Epidural  Hematoma  
eGFR  Estimated Glomerular Filtration  Rate 
ESCAPE  Endovascular Treatment for Small Cor e and Proximal Occlusion Ischemic Stroke 
EQ-5D European Quality of Life -5 Dimensions  
EVT or ET  Endovascular Therapy  
EXTEND -IA Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra -Arterial 
GA General  Anesthesia  
GI Gastrointestinal  
H, h or  hr, hrs  Hour(s)  
HCG  beta-human chorionic  gonadotropin  
HERMES  Highly EffectiveReperfusion evaluated in Multiple Endovascular Stroke 
HT1 or HT-1 Hemorrhagic Transformation  Type -1 
HT2 or HT-2 Hemorrhagic Transformation  Type -2 
ICA Internal  carotid art ery IRB NUMBER:  HSC -MS-17-0436  
age 6 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 ICH Intracranial  hemorrhage  
IRB Institutional Review  Board  
IV Intravenous  
IV-tPA Intravenous recombinant tissue plasminogen activator 
IVH Intraventricular  Hemorrhage  
kg Kilogram  
LFT Liver function  test 
LMWH  Low molecular wei ght heparin  
LOS  Length of  stay 
M1 1st segment of middle cerebral  artery  
M2 2nd  segment of middle cerebral  artery  
M3 3rd  segment of middle cerebral  artery  
mmHg  Millimeters of  mercury  
MAP  Mean arterial  pressure  
MCA  Middle cerebral  artery  
MR CLEAN  Multicent er Randomized Clinical trial of Endovascular Treatment in the Netherlands 
mRS  Modified Rankin  Scale  
mTICI  Modified Thrombolysis In Cerebral  Ischemia  
NA Not available or Not  applicable  
ND Not done  
NIHSS  National Institute of Health Stroke  Scale  
NNH  Number n eeded to  harm  
NNT  Number needed to  treat 
OR Odds  Ratio  
pH Hydrogen ion concentration 
PH1 or PH-1 Parenchymal Hematoma Type -1 
PH2 or PH-2 Parenchymal Hematoma Type -2 
Q or q Every  
rt-PA or tPA  Recombinant tissue plasminogen activator 
RCT  Randomized Clinical  Trial  
REVASCAT  Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior 
Circulation Stroke Within 8  Hours  
SAE  Serious adverse  event  
SAH  Subarachnoid  hemorrhage  
SBP Systolic blood  pressure  
SD Standard  deviation  
SDH  Subdur al Hematoma  
sICH  Symptomatic Intracerebral  Hemorrhage  
SIESTA  Sedation vs. intubation for endovascular stroke  treatment  
SWIFT -PRIME  Solitaire with the intention for thrombectomy as primary endovascular treatment trial 
tICA or TICA  Terminal Internal Carotid  Artery  
TICI  Thrombolysis In Cerebral  Ischemia  
VA Vertebral  artery  
age 6 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 1.0 BACKGROUND AND  RATIONALE  
Stroke is the fourth leading cause of death in developed nations. Each year in the US, approximately 795,000 people 
experience a new or recurrent stroke. On average , every 40 seconds, someone in the United States has a stroke.1 
Representing approximately 30 -40% of all ischemic strokes, proximal intracranial arterial occlusions result in the most 
disabling types of ischemic strokes, and are closely associated with poo r neurological outcomes at hospital discharge.2 
Recent randomized clinical trials conclusively demonstrated that early endovascular therapy (EVT) with stent -retrievers 
(i.e., embolectomy) significantly improves functional outcomes in patients with acute is chemic stroke up to 6 hours after 
onset and are recommended by the American Heart Association/Stroke Association (AHA/ASA).3-6 However, controversy 
remains regarding the optimal type of anesthesia that should be used during in EVT.7-10 The AHA/ASA guidelin es do not 
support a recommended choice of anesthesia as the selection should be individualized to the patient (Class IIb; Level of 
Evidence C).11 Further, the guidelines state that randomized trials are needed.  
 
 
1.1 Retrospective Studies of Anesthesia during Endovascular  Therapy  
Many retrospective case -control studies, propensity score analyses and post -hoc analyses of EVT trials have suggested, 
compared to CS, an association between GA and worse stroke outcomes including mortality – see table 1.12-19 In these  
studies, GA compared to conscious sedation (CS) in EVT reduced the odds of 90 -day good functional outcome (mRS ≤ 
2). 
 
Following 1:1 matching using propensity score analysis, 507 general anesthesia and 507 CS patients, the outcome of 
thrombectomy patients receiving CS had decreased in -hospital mortality, pneumonia, and lower hospital costs and lengths 
of stay when compared with patients who received general anesthesia.12 This study suffered significant selection bias, 
which compromised its conclusion. A pos t-hoc analysis of the thrombectomy patients in MR CLEAN (Multicenter 
Randomized Clinical trial of Endovascular Treatment in the Netherlands) showed better functional 90 -day outcome in the 
absence of general anesthesia, but again, patients were not randomiz ed to the type of anesthesia.17 
 
 
1.2 Randomized Trials of conscious sedation vs. general anesthesia during Endovascular  Therapy  
 
Until the recent publication of the first randomized trial testing general anesthesia vs. CS, 20 none  of these studies 
randomized patients to a particular anesthesia approach – see table 1. The SIESTA trial randomized 150 (1:1) EVT 
treated stroke patients to either GA or CS at a single institution in Germany. The primary outcome, improvements in 24 - 
hour mean NIHSS scores were nearly  identical (3.2 vs. 3.6 points in GA vs. CS, respectively). The mean difference 
between the two groups was 0.4 and not statistically significant, P=0.82. Both arms demonstrated similar rates of 
successful angiographic reperfusion (TICI 2b or 3): 89% -GA vs.  81%-CS. More GA patients had prolonged intubation, 
incidence of pneumonia and hypothermia. Despite the increased incidence of adverse events and lack of clinical 
improvement at 24 hours, GA patients were more likely to be func tionally independent (mRS ≤2) at 90 days: 37% GA vs. 
18% CS, P=0.01 (see table 1). Both in -hospital and 90 -day mortality were nearly identical in the two study  arms.  
Authors concluded SIESTA results did not support superiority of CS over GA and they recomm ended a larger, 
multicenter RCT powered to address longer -term outcomes.  
 
  
 
Table 1. Summary of clinical studies of ET and anesthesia. Shaded row indicates the lone RCT of EVT patients randomized to GA versus C S. 
 
REF  Design  Anesthesia 
Preferred  Benefit  Harm Comments  
 
12  
Retrospective 
Propensity 
Analysis   
 
Sedation  • Sedation  associated  with:  
↓hospital mortality;  
↓pneumonia;  
↓hospital costs/LOS  GA associated with:  
↑ in-hospital mortality (25% v 12%) OR=2.4, 95%CI 
1.7-3.4, p<0.001.  
↑pneumonia 17% v 9% OR=2, 95%CI 1.4 -2.96, p<0.001.  
• ICH/SAH rates similar: 11% v 12%,  p=0.62.  - 1:1 propensity score m atching 507 GA & 
507 CS  patients  
- Usage rate of GA decreased from 83.8% in 2006 
to 74% in 2013.  
 
13 Post-Hoc 
analysis of 
Multicenter 
RCT (IMS -3)  
Sedation  No significant difference in:  
- Adjusted risk of SAH (P=0.32) or sICH 
P=0.37  • GA associated  with:  
↑ in-hospital mortality - aRR 2.8; 95%CI, 1.7 - 
4.9,P<0.001  
• ↓ 90d mRS ≤2, RR 0.68; 95%CI 0.5 -0.9; P=0.006  Sedation – 269 (62%)  
GA – 147 (33.9%)  
Undetermined – 18 (4%)  
 
 
14  
Retrospective 
analysis 
(n=126)   
 
Sedation  • Intra -procedural complications lower in 
patie nts who received Sedation 6% v GA 
15% P=0.13  
• Sedation assoc with good outcome (OR 3.06, 
P=0.04)  GA associated with ↑ICU LOS: 6.5 days v 3.2 days, 
P<0.00)  Sedation – 73 (58%); GA – 53 (42%)  
 
15 Retrospective 
analysis 
(n=109)   
Sedation  Duration of procedure  & time to 
revascularization was significantly lower in 
Sedation  GA 18% greater mortality rate compared with the CS 
group ( P=0.045)  - CS – 74; GA - 35 
- GA & post procedure glucose significant 
predictors of mortality  
 
16 Retrospective 
pre-trial 
Cohort of 
MR-CLEAN 
(n=348)   
 
Sedation  • Sedation better clinical outcomes - (OR 2.1, 
95% CI, 1.02 –4.31)  
• After adjusting for pre -specified  prognostic 
factors, statistical significance was lost 
(OR1.9, 95% CI, 0.89 –4.24).  No difference in sICH or Asymptomatic ICH 
Mortal ity 
- GA group (21%) vs. Sedation (17%)  
No difference in device dissection or device -related 
complications  CS - 278 
GA – 70 
 
17 Post-Hoc 
analysis of 
RCT (MR - 
CLEAN)   
Sedation  mRS in favor of non -GA compared to control 
group (adjusted common OR 2.2, 95%CI 1.5- 
3.2. GA associated with significant (p = 0.011) effect 
modification, resulting in estimated ↓of 51% (95%CI 
31%-86%) in EVT effect compared to CS.  Treatment without GA was associated with a 
significant treatment benefit in MR CLEAN.  
18 Retrospective  
Case -Contro l Sedation  • No difference in  hemorrhage  GA associated with ↑mRS >2 at 90 days (OR 2.33) and  
also ↑mortality (OR 1.7)  Older study (2005 – 2009);  
n=980  
19 Post-Hoc 
Meta -Analysis 
of 9 studies   
Sedation  • No difference in treatment times between the 
two groups  GA associated with:  
↑mortality OR 2.6, ↑respiratory complications OR 2.1  
↓good clinical outcomes (OR = 0.43)  - GA patients with higher NIHSS presenting 
scores.  
- n=1956  
 
20  
RCT  
Monocentric  GA - no 
support for 
CS 
advantage  • No significant difference (P=0.82 ) in primary 
outcome (24 hour NIHSS) between  groups.  
• ↑ mRS ≤2 at 90d 37% -GA v. 18% CS 
without mortality  diff. GA had more:  
- hypothermia (32%,  P<0.001)  
- delayed extubation (49.3%,  P<0.001)  
- pneumonia (13.7%, P=0.03)  Only RCT that randomized EVT patients to 
either GA or CS.  
 
Sedation – 77; GA - 73 
Campbell  
(ISC 
2017)  Post-Hoc 
Meta -Analysis 
5 RCTs   
Sedation  • Both CS & GA superior compared to usual  care  
• Equivalent procedure  complications  ↑good outcomes in non -GA group (OR 1.6).  
↑ pneumonia in GA group (16% v 9%) , 
- Randomization to treatment time prolonged in GA  HERMES  collaboration;  n=1287;  NIHSS, age, 
onset to random. times comparable CS v.  GA 
 
 
SEGA Trial  Protocol  v.1.8  Page 8 of  31 IRB APPROVAL DATE: 02/03/2021  

age 9 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 A recent retrospective study of a multi -hospital administrative database between 2006 -2013, found 80% of 2515 EVT 
patients received GA, whereas 20%, received CS.21 These findings suggest the majority of neuro -interventionists 
preferred GA. Since that time, multiple retrospective studies have been p ublished (detailed in table 1) that suggest CS 
may be preferable to GA. We recently sent a questionnaire to vascular neurologists and both neurology and neurosurgery 
trained neuro -interventionalists. The aim was to determine the state of anesthesia equipoi se among physicians who 
perform or direct care for EVT stroke patients. Notably, the questionnaire was sent 4 months after publication of the 
SIESTA trial. EVT specialists were asked if a randomized trial was still needed – Figure 1. Out of 97 respondents,  the 
responses were similar.  
 
Figure 1. Results of questionnaire from comprehensive stroke center’s opinion for a current randomized trial of 
anesthesia in EVT.  
 
For thrombectomy following acute stroke, any delay will likely res ult further brain infarction. Relative to CS, general 
anesthesia may result in more delays to recanalization time.7 On the other hand, patients who receive CS are more likely 
to suffer agitation and move while on the treatment table, potentially delaying r ecanalization as well, and increasing 
procedural risk. Iatrogenic arterial rupture and inability to catheterize the occluded vessel are key concerns. There has als o 
been speculation of potential anesthetic -related worsening ischemic volume due to a vasodil atory “steal phenomenon”.7 
The cumulative dose of norepinephrine during general anesthesia was considered a predictor of an unfavorable  outcome.22 
 
GA for EVT can be administered using intravenous anesthetics, inhaled anesthetics, or a combination. There i s no clear 
standard of care as to the type of GA for this procedure: the various retrospective and prospective studies investigating 
this issue have used both. Lacking evidence of the superiority of one type of anesthetic over the other in EVT, the 
decisio n of which type to administer is based on anesthesiologist preference and/or common local practice. Different 
anesthetic techniques have differential effects on cerebral blood flow, which may affect flow to the penumbra either 
directly, or by increasing fl ow to unaffected regions (“steal phenomenon”). One retrospective study found that outcomes 
were better in patients administered an inhaled general anesthetic compared to intravenous or combination techniques.9 
 
As expected secondary to study design, previo us retrospective studies comparing the utilization of the CS vs. GA are 
severely limited by probable selection bias. The “sicker” patients with cardiovascular instability or respiratory distress, 
agitation, aphasia from dominant hemispheric stroke location , and the inability to protect their airway were typically 
treated under general anesthesia. These patients remained intubated for the same reasons after the procedure as well; 
whereas patients who were otherwise conscious and cooperative at baseline, with out airway issues, with stable 
cardiovascular and pulmonary status were selected for EVT under CS. Intuitively, patients within the former group had 
longer ICU and hospital stay, higher hospital mortality, and worse neurological and functional outcomes.  
The soundest mechanism for reducing selection bias remains randomization with allocation concealment. Most 
importantly, randomization balances all the known and unknown patient characteristics. Therefore, a randomized study 
comparing CS and GA during EVT is needed to evaluate the objective outcomes to help determine the future treatment 
paradigm.  IRB NUMBER:  HSC -MS-17-0436  
QUESTION:  
Do you think there is a n eed for a randomized 
study to evaluate the choice of anesthesia 
(sedation vs. general anesthesia) for EVT, in 
light of the published retrospective data 
suggesting better outcomes of patients 
undergoing EVT under sedation instead of 
general anesthesia, and the latest publication 
of SIESTA (a randomized study)?  
age 10 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPR OVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 2.0 STUDY  OBJECTIVES  
 
2.1 Primary Objective  
 
To evaluate the hypothesis that GA during EVT for acute ischemic stroke improves functional outcomes  at 90 days 
compared to sedation.  
 
 
 
2.2 Secondary  Objectives  
 
Evaluate safety, reperfusion, early neurological improvement, effect modification by type of GA, and quality of life in 
EVT patients randomized to GA versus sedation.  
 
 
3.0 STUDY  ENDPOINTS  
3.1 Primary  Endp oint 
 
The primary endpoint is a comparison of independent clinical outcome, defined as a modified ordinal Rankin Scale (mRS) 
at 90 days (scores 5 and 6 combined) among patients randomized to GA versus sedation. Primary analysis will be 
intention to treat ( ITT) and adjusted for stratification  variables.  
 
 
 
3.2 Secondary Clinical  Endpoints  
1) As treated analysis of primary outcome adjusted for stratification  variables  
a. Patients will be analyzed according to the type of anesthesia received (e.g., a patient randomized to 
Sedation that crosses -over to GA will be analyzed in the GA  group).  
2) Dichotomized mRS at 90 -days (0 -2 vs 3 -6) adjusted for stratification  variables.  
3) Angiographic reperfusion defined as modified TICI score ≥  2b. 
4) Early clinical improvement measured by diff erence in 24 -36 hour NIHSS  scale.  
5) Proportion of independent functional outcome at 90 days in GA patients treated with inhalational vs. intravenous 
medications.  
6) Difference in quality of life at  90-days.  
 
 
3.3 Secondary Safety  Endpoints  
1) Symptomatic intracerebral  hemorrhage within 18 -36 hours.  
1. Defined as the SITS -MOST definition: Increase in NIHSS of ≥4 points and PH -2/rPH -2.23 
2) All-cause  mortality.  
3) Rates and types of peri -procedural or device -related  complications.  
age 10 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPR OVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 3.4 Exploratory  Analyses  
 
1) Ordinal ITT and as -treated analysis of primary outcome comparing three groups (CS, GA IV, GA inhalational) 
adjusting for stratification  variables.  
2) Multivariable adjusted analysis (including stratification variables) for both primary (mRS 0 -2) and ordinal 
analysis of 90 -day mRS outcomes, to include (but not lim ited to) baseline variables known to be clinically 
associated with stroke  outcomes:  
a. Age 
b. NIHSS  
c. Time from stroke onset -to-EVT groin  puncture  
d. IV-tPA treatment before  EVT  
e. Atrial  Fibrillation  
3) Duration of time during EVT spent below a systolic blood pressure of  140mmHg.  
4) Total ICU and ventilator  days.  
5) Subgroup analyses to test for heterogeneity in patient benefit and Provider  Skill:  
a. Proximal vs. Distal occlusion location (ICA+M1 -MCA vs.  others)  
b. High -volume vs. low -volume  centers  
6) Costs from a health system  perspect ive 
 
 
 
4.0 STUDY  DESIGN  
 
4.1 Overview  
 
This trial is a multicenter, randomized, parallel -group, open -label treatment with blinded end point adjudication (PROBE). 
Patients with acute stroke who meet endovascular therapy criteria for large arterial vessel occlusion will be randomized 
1:1 to Sedation or GA. Patients randomly assigned to GA will then be randomized to either inhalational or IV anesthesia 
using a 1:1  ratio.  
 
The total estimated duration for trial completion is 2 years (18 months for enrollment, 6 months for data collection, data 
cleaning and statistical analysis); subject participation is expected for 90 days from onset of acute stroke event  
 
 
4.2 Enrollment and  Randomization  
 
Enrollment in this study is defined as the moment when the randomization process is  completed and the subject is 
assigned to a study arm. After randomization, no crossover is permitted unless either the neurovascular interventionalist 
or anesthesiologist determines the patient meets criteria as described in section 5.0  
Randomization will  occur via a secure, password -protected, web -based system. Subjects will be randomized 1:1 to GA or 
Sedation using permuted blocks and stratified by center, terminal ICA occlusion (yes/no), and time of stroke 
symptom onset (≤ 6 hours or 6 -16 hours). Patients randomized to GA will subsequently be randomly assigned in a 1:1 
ratio to either inhalational or IV anesthesia.  
 
Stroke management and endovascular therapy procedures will occur as per local site usual care. Only FDA -approved 
thrombectomy devices should be used with first line use of stent retriever. Both general anesthesia and Sedation should 
be delivered and managed by an anesthesiologist.  
age 10 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPR OVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 5.0 STUDY  POPULATION  
 
5.1 Inclusion  Criteria  
 
1. Acute ischemi c stroke due to large intracranial vessel occlusion demonstrated on CT -angiography in the 
following anterior circulation locations that will be treated by endovascular therapy  (EVT):  
a. Internal Carotid Artery (terminal “T” or “L -type” - occlusion)  
b. Middle Cere bral Artery (MCA) M1 or proximal  M2 
c. Anterior Cerebral Artery (ACA) A1 or proximal  A2 
• Patients who receive IV -tPA thrombolysis are eligible provided the drug was delivered within 4.5 hours  of 
stroke onset or last seen normal and in accordance with local hos pital standard of  care.  
2. Ages  18-90. 
3. National Institute of Health Stroke Scale (NIHSS) score  6-30 
4. Time of stroke symptom onset of last seen normal to start of EVT (defined as groin puncture) ≤ 16  hours.  
5. Limited infarct core, as defined below and adapted from the 2018 American Heart Association guidelines  28 
a. For patients presenting ≤ 6 hours from time o f symptom onset or last seen normal, Alberta  Stroke 
Program Early Computed Tomography Score (ASPECTS) ≥  6 
b. For patients presenting > 6 hours and ≤ 16 hours from time of symptom onset or last seen normal, they 
must satisfy EITHER ONE of the two following  criteria:  
i. Ischemic core by CT Perfusion or MRI/MR Perfusion < 70 mL, a ratio of volume of  penumbral 
tissue to infarct core of ≥ 1.8, and and absolute volume of penumbral tissue of ≥ 15 mL  29 
 
OR 
 
ii. For patients with NIHSS ≥ 10, infarct core of < 31 mL by CT Per fusion or MRI; For patients  with 
NIHSS ≥ 20, infarct core < 51  mL.30 
6. Subject willing/able to return for protocol required follow up  visits.  
7. No significant pre -stroke disability (modified Rankin Score must be ≤  2). 
8. Females of childbearing potential must hav e a negative serum or urine pregnancy  test. 
9. Patient or patient’s legally authorized representative has given Informed Consent according to Good Clinical 
Practices (GCP) and/or local IRB  policies.  
 
 
5.2 Exclusion  Criteria  
 
1. Coma on admission (Glasgow Coma Scale <8), need for intubation upon ED arrival, or transferred patients who 
present previously  intubated.  
2. Severe agitation or seizures on admission that preclude safe vascular  access.  
3. Loss of airway protective reflexes and/or vomiting on  admission.  
4. Predicted or known difficult  airway.  
5. Pre-existing neurological or psychiatric disease that would confound the neurological or functional  evaluations,  
e.g. dementia.  
6. Presumed septic embolus, or suspicion of bacterial  endocarditis  
7. Currently participating or has participa ted in any investigational drug or device study within 30  days.  
8. Inability to follow -up for 90 -day assessment.  
9. Known history of allergy to anesthesia  drugs.  
10. Known history or family history of malignant  hyperthermia  
age 10 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPR OVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 5.3 Crossover  Criteria  
 
1. Severe agitation or  seizures.  
2. Loss of airway protective reflexes, vomiting, or  aspiration.  
3. Inability to maintain  airway.  
4. Loss of consciousness.  
5. Hemodynamic  instability.  
6. Determination by anesthesiologist and/or neurointerventionalist that randomized method of anesthesia is 
contraindicated for some other reason (see section  5.4) 
 
5.4 NPO  Status  
 
Lack of confirmation of duration of fasting status ( nil per os; NPO ) shall, in and of itself, not be considered a 
contraindication to moderate sedation for the purposes of this study. Patient s should not be excluded from the study or 
crossed -over from sedation to GA solely due to NPO status.  
 
Rationale:  
NPO status is often unknown in patients presenting with acute ischemic stroke. Despite this, the recommendation by the 
AHA/ASA is that moderat e sedation is preferred over general anesthesia for EVT 31 and this is routinely practiced at 
stroke centers across the country. The determination of a potential subject’s eligibility for sedation should be based on the  
overall clinical picture, other risk  factors for pulmonary aspiration, and consideration of the target depth of sedation for 
this procedure (moderate  sedation).  
 
EVT for acute ischemic stroke is an emergency procedure. The American Society of Anesthesiologists’ guidelines for pre - 
procedural  fasting are intended for elective procedures32, and the guidelines for procedural sedation state that “the 
literature does not provide sufficient evidence that pre -procedure fasting results in a decreased incidence of adverse 
outcomes in patients undergoi ng either moderate or deep sedation,” leading the task force to conclude that “in urgent, 
emergent, or other situations in which gastric emptying is impaired, the potential for pulmonary aspiration of gastric 
contents must be considered in determining (1) the target level of sedation, (2) whether the procedure should be delayed, 
or (3) whether the trachea should be protected by intubation.” 33 The American College of Emergency Physicians has 
developed specific guidelines that support the use of extended -duration moderate sedation for standard -risk patients 
undergoing urgent procedures, and for high -risk patients undergoing emergency procedures.34 See Appendix III.  
age 10 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPR OVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 6.0 STUDY  PROCEDURES  
 
All subjects who are enrolled into the trial will be followed for 90 days (±  10) unless they withdraw early from the trial, 
expire before the 90 day follow up window is reached, or are lost to follow up. The study event schedule is illustrated in 
Table 2.  
 
 
6.1 Informed  Consent  
 
Written informed consent Written informed consent or ele ctronic consent will be obtained for all subjects who are 
screened and meet the trial inclusion/exclusion criteria. If sites choose to utilize electronic consent, the method of 
electronic consent used will be based on each individual institution’s choice, as approved by the site’s IRB. In the event 
that IRBs of participating centers determine the trial meets criteria for exception from informed consent (EFIC), sites will 
have the option to pursue local procedures to include community consultation, etc. Belo w, we provide explanations that 
justify the use of delayed or exception from informed consent in this particular population.  
 
The trial compares two anesthesia approaches for EVT delivered as usual care. We have demonstrated clinical equipoise 
in participa ting stroke centers of excellence. Therefore, the trial meets criteria for comparative effectiveness  research.  
Participation in SEGA should never delay the time -sensitive nature of providing emergent reperfusion therapy in acute 
ischemic stroke. In additio n, a significant proportion of these severe stroke patients are air -transported to the 
comprehensive stroke centers (CSC) and family members must drive from the outlying hospital to the CSC. Due to the 
expected stroke severity routinely encountered with pr oximal intracranial occlusions, the majority of patients will be 
suffering from either aphasia (language disturbance of either comprehension or expression) or severe neglect (inability to 
understand or acknowledge they are suffering a stroke). Hence, the m ajority of patients will be unable to provide 
informed consent due to lack of capacity. Unfortunately, the majority of legal next of kin fail to arrive before the 
commencement of EVT procedures; including the transfer from the emergency department to the a ngio suite for  EVT.  
 
As a result, traditional written approach to informed consent in this patient population is rarely feasible and will impact 
study recruitment, results and generalizability. First, the trial would recruit at a very slow pace and enrollm ents will be 
predominantly a less -severe subpopulation of strokes. Second , it is well established across clinical research that the 
patients who benefit the most from effective interventions are usually those most severely affected. Thus, our estimations 
of treatment differences would result in decreased probability of observing a difference between the study arms.  
Critically, traditional written emergent consent will inherently delay EVT procedures and possibly result in worse clinical 
outcomes. Pooled ana lyses from EVT RCTs have demonstrated that minor delays to arterial reperfusion of 20 minutes are 
associated with worse clinical outcomes. Third , participation in a clinical trial could directly benefit the patient and 
ultimately society if a new treatment  is discovered.  The inability to participate in promising research for the most 
severely affected patients is sometimes interpreted as a breach of the ethical principle of justice. The basic concept of 
distributive justice, as it relates to clinical resea rch, should not categorically exclude certain subgroups with clinically 
relevant characteristics such as disease severity, sex, age, etc. This discrimination is unjust and results in skewed 
generalizable knowledge that guides health care  practices.  
We reco gnize that emergency research such as this trial or any research that requires study -related research outcomes will 
require subsequent written consent from the patient of legal next of kin. Therefore, each site must make a reasonable 
attempt to reach famil y members that are available in the hospital or will be arriving within 15 minutes. For patients 
enrolled via EFIC, explicit written consent must be obtained during the study period of 90 -days. Usually, this should 
occur within 5 days of enrollment during the hospitalization. Ultimately, each participating center must follow their local 
IRB’s decision regarding consent in this trial  
150 minut  
 
age 15 of 31  
: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
 
Table 2 . Schedule of events.  
 
 
ASSESSMENTS  VISITS  
Baseline  <16 hours from stroke 
onset/LSN  18-36 hours  Day 7 or discharg e, 
whichever occurs first  90 ± 15 days  
Demographics  Y  Y   
Medical History  Y     
Stroke History  Y  Y   
mRS  Y   Y* Y 
EQ-5D     Y* 
NIHSS  Y  Y Y  
EVT Procedure Variables   Y    
Imaging assessment 
Parenchymal - CT or  
MRI  
Arterial – CTA or MRA   
Y 
Y   
Y   
Assess for adverse events   Y Y Y  
Note : Except those notated by *, all procedures and assessments are collected a usual care for acute ischemic stroke patients.  
 
6.2 Treatment Period  
 
6.2.1 Endovascular Procedure and Time  Metrics  
 
As recommended by the AHA/ASA, the first line therapeutic embolectomy device should be a stent retriever. The use of 
a proximal balloon guide catheter or a large -bore distal -access catheter, rather than a cervical guide catheter alone, in 
conjunction with stent retrievers may be benefic ial. Future studies should examine which systems provide the highest 
recanalization rates with the lowest risk for nontarget embolization  
 
Additional EVT therapies including, but not limited to, intra - or extracranial angioplasty ± stenting; antithrombotic s (oral, 
IV or IA antiplatelets or anticoagulants) intra -arterial thrombolytics; are left to the decision of the local treatment team.  
Conversely, in general, off -label use or therapies not supported by scientific evidence are discouraged. Importantly, the  
use of these therapies will not be considered a protocol deviation.  
 
Time to reperfusion in EVT trials is correlated with improved outcomes and societies have published position statements 
on timing metrics. The current protocol provides guidance for cent ers derived from these recommendations (see table 3).  
26 
Table 3 . SEGA recommended guidelines for timing metrics  
 
Acute Stroke Time Metric  Maximal Target 
Time  
Door to Imaging (parenchymal imaging – non-contrast CT, MRI)  15 minutes  
Door to IV -tPA bolus  60 minutes  
Door to Groin Puncture  90 minutes  
Angiosuite arrival to Groin Puncture  20 minutes  
Door to Reperfusion  eIsRB NUMBER  
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
 
 
The following intra -procedure (thrombectomy) variables will be collected (see CRFs for further details):  
• Door to puncture  time 
• Decision of intervention to puncture  time 
• Time from puncture to first recanalization  attempt  
• Time to Revascularization: defined as arterial puncture to TICI ≥ 2b revascularization or end of  procedure.  
• Revascularization assessment at the end of the proc edure (using Thrombolysis in Cerebral) Infarction (TICI) 
score.  
• Number of recanalization attempts (i.e. thrombectomy attempts or stent -retriever  passes)  
• Name of the mechanical retrieval device  used 
• Utilization of aspiration  technique  
• Failure to reach  clot 
 
6.2.2 Angiographic measures of arterial perfusion and  collaterals  
 
Using angiography, the modified TICI (mTICI) score is defined according to the level of blood flow through an occlusion 
site and consists of 5 discrete categories (table 4a).  
 
 
Table 4a . Angiogr aphic scoring of large vessel occlusions and reperfusion.  
 
mTICI  
score  Definition  
0 No Perfusion  - No antegrade flow beyond the point of occlusion  
1 Penetration with Minimal Perfusion  - The contrast material passes beyond the area of obstruction but fail s to opacify 
the entire cerebral bed distal to the obstruction for the duration of the angiographic run.  
 
 
2 Partial Perfusion  - Contrast material passes beyond the obstruction and opacifies the arterial bed distal to the 
obstruction; However, the rate of  entry of contrast into the vessel distal to the obstruction and/or its rate of clearance 
from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by 
the previously occluded vessel, e.g., the opposi te cerebral artery or the arterial bed proximal to the obstruction.  
• 2a Only partial filling (< 50%) of the entire vascular territory is  visualized.  
• 2b Filling of > 50% all of the expected vascular territory is visualized, but the filling is slower than  normal. 
 
3 Complete Perfusion  - Antegrade flow into the bed distal to the obstruction occurs as promptly as into the obstruction 
and clearance of contrast material from the involved bed is as rapid as from an uninvolved other bed of the same vessel 
or the op posite cerebral artery.  
 
 
Cerebral collaterals play a key role in determining outcome in endovascular treatments for acute ischemic stroke. In 
addition, given the hypothesized effect of general anesthesia on blood pressure and cerebral perfusion, collater al grade 
may be a particularly relevant determinant of outcome in this cohort. Collaterals will be graded from the angiograms by 
society guidelines, as shown in Table 4b 25 
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
 
 
Table 4b . Angiographic scoring of cerebral collaterals  
 
 
Collateral  
score  Definition  
0 No collaterals visible to the ischemic site.  
1 Slow collaterals to the periphery of the ischemic site with persistence of some of the defect.  
2 Rapid collaterals to the periphery of the ischemic site with persistence of some of the defect and t o only a 
portion of the ischemic territory.  
3 Collaterals with slow but complete angiographic blood flow to the ischemic bed by the late venous phase.  
 
4 Complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by ret rograde 
perfusion.  
 
6.3 90-day (± 15 days)  Follow -up 
 
The study participation will be considered completed after the 90 day follow up visit has been completed. If for any 
reason the patient cannot visit the clinic/hospital for the follow up, the Investigator or research staff should ask permission 
from the patient and family if an in -person visit could take place at the current dwelling facility to assess patient’s 
neurological condition. In the event that in -person assessment is not possible, research team -members should conduct a 
phone interview. In the event that the patient cannot be reached or is unable to answer assessment questions, their 
caregiver or family member can be  questioned.  
 
The patient’s quality of life will be assessed using the EQ -5D provide  a numerical measure of the patient’s health utility. 
In the event the patient is unable to communicate or understand the questions, his/her next of kin (proxy) who knows the 
most about their current health state will be asked to fill out these questionnai res on behalf of the patient. Importantly, the 
proxy will be instructed to fill answer the quality of life questionnaires from the patient’s perspective – knowing 
everything they know about the patient, how would they answer if they capable.  
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 7.0 ANESTHESIA  GUIDANCE  
 
 
7.1 Sedation  
 
Sedation will be provided under the supervision of an anesthesiologist using a combination of fentanyl, midazolam, 
dexmedetomidine infusion (with or without loading dose), remifentanil infusion, and/or low -dose propofol by intermittent 
bolus or infusion, with a target Richmond Agitation Sedation Scale (RASS) score of -1 to -3 (light to moderate sedation – 
responds to verbal stimulation; see Appendix II).  
 
Sedation patients who do not tolerate sedation (e.g., patient agitation, airway diff iculty, loss of consciousness, aspiration, 
cardiovascular instability) should be converted to Inhalational GA and the corresponding protocol followed.  
 
7.2 General  Anesthesia  
 
Induction of anesthesia will be achieved with propofol and/or etomidate; muscle para lysis with succinylcholine or non - 
depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl as deemed appropriate by the 
anesthesiologist. Hyperventilation should be avoided during induction.  
 
Intravenous : Maintenance of anest hesia will be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of 
non-depolarizing paralytic and fentanyl (and/or remifentanil infusion) as needed.  
 
Inhalational : Maintenance of anesthesia will be achieved with sevoflurane 1% to 2% or de sflurane 3% to 6% end -tidal 
concentration with redosing of non -depolarizing paralytic and fentanyl (and/or remifentanil infusion) as needed.  
 
 
 
7.3 Blood Pressure  Management  
 
Systolic blood pressure (SBP) should be maintained at 140 to 180 mmHg with pressors ( e.g., phenylephrine, 
norepinephrine) or antihypertensives (e.g., nicardipine, labetalol) as needed. Diastolic blood pressure should be 
maintained <105 mmHg.  
 
In patients who are reperfused after EVT (defined as achieving TICI 2b or TICI 3), SBP should be m aintained at 140 
mmHg in the first 24 hours to minimize the risk of reperfusion -related brain hemorrhage. Blood pressure of patients who 
fail to achieve recanalization will be left to the discretion of the individual stroke centers’ usual care.  
 
 
 
7.4 Anesthes ia Monitoring  
 
Invasive hemodynamic monitoring should be attempted prior to induction of GA to allow for tight hemodynamic control. 
To limit any delay in time to revascularization, attempts to establish peripheral invasive arterial access should be limited  
to 5 minutes; after that time, continuously -cycled non -invasive blood pressure measurements should be performed until 
invasive hemodynamic monitoring can be achieved through the femoral sheath. SBP should be maintained at 140 to 180 
mmHg throughout with p henylephrine and/or norepinephrine as needed. Patients who are converted from sedation who 
already have invasive hemodynamic monitoring through the femoral sheath do not need additional arterial access.  
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 End-tidal CO 2 concentration (PETCO 2) in patients rec eiving GA should be maintained at 35 to 40 mmHg (corresponding 
to a PaCO 2 ~40-45 mmHg).  
 
All patients who are deemed medically appropriate for extubation should be awakened and extubation attempted at the 
conclusion of the procedure. Muscle paralysis shoul d be reversed at the conclusion of the procedure using neostigmine or 
sugammadex; those patients with deep neuromuscular blockade that precludes reversal with neostigmine should be 
reversed with an adequate dose of sugammadex to avoid unnecessary prolonged  intubation.  
 
 
7.5 Anesthetic Data  Collection  
 
The following intra -procedural anesthesia variables will be collected:  
• Anesthetic agents used for GA or  sedation  
• PETCO 2 q5 min in GA  group.  
• RASS score q15 min in sedation  group.  
• Oxygen saturation q15  min 
• Continuou s BP measurements from an electronic anesthetic record for determination of time spent with SBP <140 
mmHg.  
• Utilization of norepinephrine, phenylephrine, or other vasopressors as well as total dose  administered.  
• Documentation of post -procedure extubation or  the reason for remaining  intubated.  
• Reason of crossover of anesthesia modality (sedation to GA) – patient agitation, airway difficulty, loss of 
consciousness, aspiration, cardiovascular  instability  
 
 
8.0 SAFETY  
 
8.1 Adverse  Events  
 
An adverse event could include any of the following events, which develop or increase in severity during the course of the 
study:  
• Any signs or symptoms whether thought to be related or unrelated to the condition under  study;  
• Any clinically significant laboratory  abnormality;  
• Any abnorma lity detected during physical  examination.  
 
These data will be recorded on the appropriate CRFs, regardless of whether they are thought to be associated with the 
study arm treatment. Signs or symptoms will be graded by the Investigator as mild, moderate or  severe according to the 
following definitions:  
Grade:  Definition  
Mild:  Causing no limitation of usual activities 
Moderate:  Causing some limitations of usual activities 
Severe:  Causing inability to carry out usual  activities.  
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 8.2 Serious Adverse Events  (SAEs)  
 
A serious adverse event is defined as any event that suggests a significant hazard, contraindication, side effect or 
precaution. A serious adverse event includes any event that:  
• Results in death;  
• Is life  threatening;  
• Results in prolongation of existing  hospitalization;  
• Results in persistent or significant  disability/incapacity;  
• Important or significant medical events that require medical or surgical intervention, based upon appropriate 
clinical  judgment.  
 
The Investigator must assess the relationship of t he adverse event to the study device using the following criteria 
categories and definitions:  
• Unrelated  - The adverse event is determined to be due to a concurrent illness or effect of another device/drug and 
is not related to the type of anesthesia  utiliz ed. 
• Possible  - The adverse event is determined to be potentially related to the treatments received for anesthesia and 
an alternative etiology is equally or less likely compared to the potential relationship to the type of anesthesia 
provided.  
• Probable  - There is a strong relationship to the type of anesthesia, or recurs on re -challenge, and another etiology 
is unlikely.  
• Highly Probable  - There is no other reasonable medical explanation for the  event.  
 
 
8.2.1 Reporting of Serious Adverse Events  
 
Each clinic al site will follow their internal policies for reporting SAEs to their IRB. In addition, sites will alert the UT - 
Houston data -core within 24 -hours of becoming aware of the SAE. This alert will be relayed to the study PIs for review. 
If an SAE is confirme d, the coordinating site will be responsible for reporting to the DSMB as outlined in the DSMB 
charter. DSMB reports will be forwarded to all participating clinical sites for local IRB submission.  
 
The study sponsor is responsible for the coding and report ing any adverse event required by regulatory authorities. The 
study sponsor will code AEs using MedDRA (Medical Dictionary for Regulatory Affairs). Unanticipated serious adverse 
events that meet criteria for FDA submission per 21 CFR part 803 will be submi tted by the study sponsor.  
 
 
8.3 Follow -Up of Adverse  Events  
 
All adverse events will be collected from the time of randomization and monitored until day 7 or hospital discharge, 
whichever occurs first. AEs that do not meet criteria for resolution will be cate gorized as on -going after day 7 or 
discharge.  
age 16 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 9.0 STATISTICAL  METHODS  
The study will be conducted under a common umbrella protocol developed by UTHealth with the itention of combining 
data from all satellite centers for analysis. Each participating site will give utmost importance to follow the study  protocol 
to maintain consistency in study execution at all centers. Detailed analysis plan for all pre -specified outcome measures 
are located in separate statistical analysis  plan.  
 
9.1 Sample Size  Justification  
 
A ma ximum of 260 patients, 130 per arm will be randomized. Assuming a neutral prior probability (centered at OR of  1.0, 
95% prior interval: 0.3 –3.0) for the intervention effect, the sample size provides 80% power that General Anesthesia 
improves outcome (lower  ordinal mRS) compared to Sedation if the true OR is >1.50. Monte Carlo simulations were 
performed using R to estimate the Bayesian power of the study for the primary outcome measure.  We assumed a 
threshold of 80% posterior probability of the OR >1.0 to d eclare effectiveness. See Appendix II for summary of 
simulation  results.  
 
9.2 Statistical  Analyses  
 
Intent -to-treat analyses will be performed. To summarize the data, descriptive statistics will be used. Demographics, vital 
signs, laboratory variables, stroke type and duration from onset of symptoms will be summarized for each treatment arm. 
Vital signs taken during the treatment period will be displayed graphically. In addition to ICH, other medical events will 
be tabulated by body system and severity.  
 
Primar y analyses will focus on comparing GA (combining inhalational and IV anesthesia) to sedation. All analyses will 
be conducted under a Bayesian paradigm to obtain estimates of odds ratio (OR) for primary outcome (ordinal mRS), 
relative risk (RR) for binary o utcomes, and probability of treatment benefit or harm (quantities that cannot be obtained 
from frequentist analyses). For the treatment effect, we will use a neutral prior centered at OR of 1.0 with 95% prior 
interval of 0.3 -3.0. This prior assumes a prior i equipoise and excludes large treatment effects. Weakly informative priors 
will be used for all other parameters to exclude large treatment effects.24 
 
Generalized linear mixed models will be used to analyze all outcomes and will include treatment group, terminal ICA 
occlusion and time from onset of symptoms (stratification variables) as covariates and center (stratification variable) as a 
random effect to account for center variability. For the primary outcome of ordinal mRS at 3 months (scores 5 and 6 
combined), we will use an ordinal logistic model. For binary outcomes we will use log binomial (or logistic in case of 
non-convergence) models to directly estimate relative risks (or odds ratios) and 95% CIs. The prior for the treatment 
effect will be a Norm al (0, sd=0.57) in the log OR/RR scale. The prior for the intercept will be Normal (0, sd=10) and 
Normal (0,1) for other covariates in the model. A half -Normal(0,1) prior will be used for the standard deviation of the 
center random effect. For non -binary o utcomes, we will select the best fitting models and use neutral, weakly informative 
priors that exclude large treatment effects. We will examine residuals from each model to ensure reasonable adherence to 
the assumptions of the models.  
 
If, despite randomi zation with stratification for center, tICA, and time from onset of symptoms, any important differences 
between intervention groups occur in baseline variables related to outcome, secondary analyses will be performed 
controlling for these factors.  
 
For the  primary outcome of ordinal mRS at 3 months, a secondary analysis will be conducted comparing CS to 
inhalational anesthesia and to IV anesthesia adjusting for the stratifying variables. Models and priors will be the same as 
for the primary analysis.  
ource docu  
age 22 of 31  
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
 
9.3 Missing Data  
 
If patients are lost to follow -up at the 90 -day end of study evaluation, the worst -case scenario will be entered into the 
database (i.e., mRS = 6). In the event that the percent of patients lost to follow -up exceeds 5%, we will use multiple 
impu tation methods. This technique quantifies the uncertainty due to the missing data.  
 
 
9.4 Safety  Monitoring  
 
Formal interim analyses of safety will occur when 100 and 200 patients are enrolled. Safety endpoints will consist of 
intracerebral hemorrhage within 18 -36 hours and death. Bayesian interim monitoring will be used to assess whether 
systematic differences are evident among the treatment groups for the occurrence of the interim safety analysis endpoint. 
The posterior probability that either treatment group has a higher incidence of the interim safety analysis endpoint will be 
determined. These posterior probabilities for safety will be assessed using the log -binomial regression model with 
covariates, described more completely in section 9.2. Either treatment  will be considered harmful (i.e., the DSMB may 
consider termination of the trial) if the posterior probability of treatment harm in one treatment arm compared to the other 
exceeds 97.5%. In addition to reporting the above posterior probability, the 95% cr edible interval for the RR, and the 
entire posterior distribution of RR will be presented graphically to the DSMB in order to assure a full appreciation of the 
range of possible values of each RR.  
 
9.5 Interim Efficacy  Analysis  
 
One interim analysis is planned  after the first n=132 patients (50% of data accrual) have been randomized and have 
completed the 3 -month primary outcome assessment. Ordinal mRS outcome will be compared between GA and CS 
groups using a Bayesian logistic model detailed in section 9.2. The  same neutral priors will be used to calculate posterior 
probabilities of benefit for either treatment group. Posterior median OR and 95% intervals will also be calculated.  
 
During the interim analyses of efficacy, the DSMB may consider termination if the posterior probability of benefit 
(improving independent clinical outcome) of either treatment arm compared to the other is greater than 95%.  
Given that this is a comparative effectiveness trial, no interim futility analyses will be conducted since they are  not 
appropriate for evaluating therapies already in use.27 
 
10.0 DATA  MANAGEMENT  
10.1 Data  Collection  
 
Detailed clinical data collection will be performed using an established standard method approved by each site’s IRB. 
Data will be de -identified and recorded init ially on paper CRFs and then transferred to the study’s secure web -based 
application.  
 
Every reasonable effort should be made to complete data entry within one week of data collection. Data discrepancies 
may be queried during ongoing review of data by the trial’s data coordinating center (DCC) or may be identified and 
queried during remote or in -person monitoring visits. Data monitoring will be performed to verify data accuracy and 
ensure queries are resolved. The Principal Investigator or Sub -investigator must ensure the accuracy and completeness of 
the recorded data and then provide his/her electronic signature on the appropriate CRFs.  
 
Each participating center will provide appropriate source documentation for data monitoring. Data monitoring can take 
place either re motely (revi ew of eCRFs  compared with uploaded, d eidentifi ed s mIRenBtsN) UorMiBn-EpRe:rsHoSnCb-yMaS-17-0436  
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 designee of the trial PI. Remote data monitoring will require the site to scan the appropriate source documents. After 
scanning, local  sites will be required to redact all patient identifiers. Finally, the redacted file will be saved and uploaded 
to the trial website’s secure repository. The DCC will be responsible for comparing the eCRF data and the uploaded 
source documents.  
 
 
11.0 STUDY CO MMITTEES AND CORE  LABS  
 
11.1 Steering  Committee  
 
The steering committee will be responsible for oversight of the overall conduct of the study. These duties include 
protocol development and amendments, study progress, and overall data quality and integrity. The Steering Committee 
will oversee dissemination of study results through appropriate scientific meetings and publications. The Steering 
Committee may select additional investigators, based on enrollment, to participate on a Publication Committee. The 
Publica tion Committee will participate in the review and approval of all requests for data analysis, abstract and 
manuscript preparation and journal submission.  
 
11.2 Data Safety Monitoring  Committee  
 
The Data Safety Monitoring Committee (DSMB) will include specialist s in stroke neurology, neuro -intervention and 
biostatistics, none of whom are participating in the trial or have affiliation with the trial sponsor, UTHealth. The DSMB is 
responsible for monitoring subject safety through pre -defined, periodic review of the  clinical study safety data. Details 
regarding DSMB responsibilities, qualifications, membership, meeting frequencies, and procedures are outlined in the 
DSMB charter.  
 
The trial’s un -blinded biostatistician will assist the data -core in preparing blinded D SMB reports. Data will be supplied 
to, and reviewed by, the DSMB as tables and/or figures. The DSMB can request more data. At each review the DSMB 
will evaluate whether the study should continue unchanged, require modification/amendment or be closed to enr ollment 
and will inform the trial Co -PIs. 
 
The principal investigator (study sponsor), DSMB or the Institutional Review Board (IRB) have the authority to 
terminate, suspend, or require trial modifications.  
 
11.3 Imaging Core  Labs  
 
An independent imaging core la b will blindly review baseline parenchymal and vascular imaging that is performed as 
each site’s routine care of acute ischemic stroke patients who may be eligible for EVT. The image -core interpretations of 
all neuroimaging will serve as the data source fo r analyses such as ASPECTS score, hemorrhage and hemorrhage 
classification (see table 5) and angiographic measures of occlusion, reperfusion and collateral grade (see table 4).  
Baseline imaging will usually include a non -contrast CT of the head, CT -angiogr am of the head +/ - neck and to a lesser 
degree, a CT -perfusion of the head. According to local practice, baseline MRI and MRA are also accepted.  
 
Follow -up neuroimaging (CT or MRI) that is routinely collected between 18 -36 hours post thrombolysis or EVT wi ll be 
used to determine the presence of infarction and hemorrhage. Conventional cerebral angiograms will be assessed for pre - 
intervention (e.g., diagnostic [first intracranial run] angiogram) clot location and TICI score. Reperfusion, graded using 
the mod ified TICI reperfusion score, will be recorded by the imaging core lab post EVT. Additional angiographic scales 
will be assessed including but not limited to collateral flow grade. All neuroimaging will be de -identified at the local site  
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 and submitted to the sponsor DCC either digitally in DICOM format via a secure FTP portal or saved to a CD -ROM disc 
and mailed directly to the DCC.  
 
Table 5 . Definition and description of intracranial hemorrhage.  
 
Intracranial 
Hemorrhage  Definition  
HT-1 Hemorrhagic Transf ormation Type 1. Small, scattered petechiae within ischemic field without 
mass effect.  
HT-2 Hemorrhagic Transformation Type 2. Confluent petechiae within ischemic field without mass 
effect  
PH-1 Hematoma within ischemic field with some mild space -occupyin g effect but involving ≤ 30% of 
the infarcted area  
PH-2 Hematoma within ischemic field with space -occupying effect involving > 30% of the infarcted area  
RIH Any intraparenchymal hemorrhage remote from the ischemic field  
rPH-2 PH-2 remote from the ischem ic field  
IVH Intraventricular hemorrhage  
SDH  Subdural Hematoma. Blood between the dura mater and the arachnoid mater  
EDH  Epidural Hematoma - Blood between the dura mater and the skull  
SAH  Subarachnoid hemorrhage  
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 12.0 REFERENCES  
 
1. Roger,  V.L.,  et al., Heart  Disease  and Stroke  Statistics —2012  Update  A Report  From  the American  Heart 
Association. Circulation, 2012. 125(1): p.  e2-e220  
2. Smith, W.S., et al., Prognostic significance of angiographically confirmed large vessel intracranial occlusion in 
patients p resenting with acute brain ischemia. Neurocrit Care, 2006. 4(1): p.  14-7 
3. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic  stroke.  
N Engl J Med. Jan 1 2015;372(1):11 -20. 
4. Campbell BC, Mitchell PJ, Kl einig TJ, et al. Endovascular therapy for ischemic stroke with perfusion -imaging 
selection. N Engl J Med. Mar 12  2015;372(11):1009 -1018.  
5. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic 
stroke. N Engl J Med. Mar 12  2015;372(11):1019 -1030.  
6. Saver JL, Goyal M, Bonafe A, et al. Stent -retriever thrombectomy after intravenous t -PA vs. t -PA alone in stroke. N 
Engl J Med. Jun 11  2015;372(24):2285 -2295.  
7. Avitsian R, Somal J. Anesthetic management for intra -arteri al therapy in stroke. Current opinion in  anaesthesiology.  
Oct 2012;25(5):523 -532. 
8. Gupta R. Local is better than general anesthesia during endovascular acute stroke interventions. Stroke; a journal of 
cerebral circulation 2010; 41:  2718 –2719.  
9. Brekenfeld C, Mattle HP, Schroth G. General is better than local anesthesia during endovascular procedures. Stroke; 
a journal of cerebral circulation 2010; 41:  2716 –2717.  
10. John N, Mitchell P, Dowling R, Yan B. Is general anaesthesia preferable to conscious sedation in th e treatment of 
acute ischaemic stroke with intra -arterial mechanical thrombectomy? A review of the literature. Neuroradiology 
2013; 55: 93 –100. 
11. Powers WJ, Derdeyn CP, Biller J, et al. American Heart Association Stroke Council. 2015 American Heart 
Associati on/American Stroke Association focused update of the 2013 guidelines for the early management of 
patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals  from 
the American Heart Association/American Str oke Association. Stroke  2015;46:3020 –3035.  
12. McDonald JS, Brinjikji W, Rabinstein AA, Cloft HJ, Lanzino G, Kallmes DF. Conscious sedation versus general 
anaesthesia during mechanical thrombectomy for stroke: a propensity score analysis. Journal of  neurointer ventional 
surgery.  2015;7(11):789 -794. 
13. Abou -Chebl A, Yeatts SD, Yan B, . Impact of General Anesthesia on Safety and Outcomes in the Endovascular  Arm 
of Interventional Management of Stroke (IMS) III Trial. Stroke; a journal of cerebral circulation 2015; 46:  2142 – 
2148.  
14. Jumaa MA, Zhang F, Ruiz -Ares G, . Comparison of safety and clinical and radiographic outcomes in endovascular 
acute stroke therapy for proximal middle cerebral artery occlusion with intubation and general anesthesia versus the 
nonintubated sta te. Stroke; a journal of cerebral circulation 2010; 41:  1180 –1184.  
15. Li F, Deshaies EM, Singla A, et al. Impact of anesthesia on mortality during endovascular clot removal for acute 
ischemic stroke. J Neurosurg Anesthesiol 2014; 26:  286–290. 
16. van den Berg LA,  Koelman DL, Berkhemer OA, et al. Type of anesthesia and differences in clinical outcome after 
intra-arterial treatment for ischemic stroke. Stroke; a journal of cerebral circulation. May 2015;46(5):1257 -1262.  
17. Berkhemer OA, van den Berg LA, Puck S.S. Frans en, et. al. The effect of anesthetic management during  intra- 
arterial therapy for acute stroke in MR CLEAN. Neurology 2016;87:  656-664. 
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 18. Bösel, J. (2015), Sedation vs. Intubation for Endovascular Stroke TreAtment (SIESTA) – a randomized  monocentric 
trial. Int J Stroke, 10: 969 –978. doi:10.1111/ijs.12488  
19. Sivasankar C, Stiefel M, Miano TA, et al. Anesthetic variation and potential impact of anesthetics used during 
endovascular management of acute ischemic stroke. J Neurointervention Surg 2015. Epub,  doi:10.1 136/neurintsurg - 
2015 -011998.  
20. Mundiyanapurath S, Stehr A, Wolf M, et al. Pulmonary and circulatory parameter guided anesthesia in patients with 
ischemic stroke undergoing endovascular recanalization. Journal of neurointerventional surgery. Mar 16  2015.  
21. Wah lgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for  acute 
ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke -Monitoring Study (SITS -MOST): an 
observational study. Lancet 2007; 369:  275–282. 
22. Pedroza C, Han W, Truong VT, Green C, Tyson JE. Performance of informative priors skeptical of large treatment 
effects in clinical trials: A simulation study. Stat Methods Med Res. 2015 Dec 13. pii:  0962280215620828.  
[Epub ahead ofprint] PubMed PMID: 26668090.  
25.  Higashida, R. T. et al. Trial design and reporting standards for intra -arterial cerebral thrombolysis for acute ischemic 
stroke. Stroke; a journal of cerebral circulation 34, e109 –37 (2003).  
26. McTaggart RA, Ansari SA, Goyal M, et al. Initial hospital manag ement of patients with emergent large vessel 
occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery.  J 
NeuroIntervent Surg  2017;9:316 –323. 
27. Wittes J. Discussion of paper by Korn and Freidlin. Am J Bi oeth. 2011 Mar;11(3):13 -4. doi: 
10.1080/15265161.2010.546480.  
28.  William  J. Powers,  Alejandro  A. Rabinstein,  Teri Ackerson,  Opeolu  M. Adeoye,  Nicholas  C. Bambakidis,  Kyra 
Becker, José Biller, Michael Brown, Bart M. Demaerschalk, Brian Hoh, Edward C. Jauch, C helsea  S. 
Kidwell, Thabele M. Leslie -Mazwi, Bruce Ovbiagele, Phillip A. Scott, Kevin N. Sheth, Andrew M. 
Southerland,  Deborah  V. Summers  and David  L. Tirschwell  on behalf  of the American  Heart  Association  Stroke 
Council Stroke.  2018;49:e46 -e110,  
29. G.W. Alber s, M.P. Marks, S. Kemp, S. Christensen, J.P. Tsai, S. Ortega ‑Gutierrez, R.A. McTaggart, M.T.  Torbey,  
M. Kim‑Tenser, T. Leslie ‑Mazwi, A. Sarraj, S.E. Kasner, S.A. Ansari, S.D. Yeatts, S. Hamilton, M. Mlynash, J.J. 
Heit, G. Zaharchuk, S. Kim, J. Carrozzella, Y.Y. Palesch, A.M. Demchuk, R. Bammer, P.W. Lavori, J.P. Br oderick, 
and M.G. Lansberg, for the DEFUSE 3 Investigators* Thrombectomy for Stroke at 6 to 16 Hours with Selection by 
Perfusion Imaging N Engl J Med 2018;378:708 -18. DOI: 10.1056/NEJMoa1713973  
30.  Nogueira  RG, Jadhav  AP, Haussen  DC,et  al. Thrombectomy  6 to 24 hours  after stroke  with a mismatch  between 
deficit and infarct. N Engl J Med 2018; 378:  11-21. 
31. Powers WJ, Derdeyn CP, Biller J, et al. American Heart Association Stroke Council. 2015 American Heart 
Association/American Stroke Association focused update o f the 2013 guidelines for the early management of 
patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals  from 
the American Heart Association/American Stroke Association. Stroke  2015;46:3020 –3035.  
32. Amer ican Society  of Anesthesiologists  Practice  Guidelines  for Preoperative  Fasting  and the Use of Pharmacologic 
Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology.  2017;126:376 –393. 
33. American Society of Anesthesiologists. Practice guidelines for sedation and analgesia by  non-anesthesiologists. 
Anesthesiology.  2002;96:1004 -1017.  
34. Green  SM, Roback  MG, Miner  JR, Burton  JH, Krauss.  Fasting  and emergency  department  procedural  sedation  and 
analgesia: a consensus -based clinical practice advisory. Ann Emer g Med. 2007  Apr;49(4):454 -61. 
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 13.0 APPENDICES  
Page 
Appendix I. Richmond Agitation  Sedation Scale…  ................................ ................................ ...............  27 
Appendix II.  SEGA simulation results of  Bayesian power  28 
analysis………………………………………………....  
Appendix III. Prudent limits of targeted depth and length of ED procedural sedation and analgesia 
according to presedation assessment of aspiration  risk …………………………………………  30 
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 Appendix  I. Richmond Agitation Sedation Scale  (RASS)  
 
 
 

age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 Appendix  II. Monte Carlo simulation re sults of Bayesian power  
 
1. Primary outcome of ordinal mRS at 90  days 
 
Based on data from 3 previous trials, we assumed rates of 10%, 14%, 11%, 19%, 18%, and 28% for mRS outcome  
categories of (0, 1, 2, 3, 4, 5+6) for Conscious Sedation group. Data from ANSTRO KE trial was downweighted 50%. We 
assumed a treatment effect size corresponding to an OR=1.53 (GA group having better outcomes). We simulated 10,000 
trials for two total sample sizes, N=265 and N=250 and assuming rates of follow -up of 100%, 98%, 97%, 95%, and 90%. 
We calculated power (Table 1) to declare benefit based on range of thresholds to declare effectiveness (i.e., 
Pr(OR>1)>threshold). For analyses, we used a neutral prior centered at OR of 1.0 (95% CI: 0.3 –3.0) for the treatment 
effect and ordinal l ogistic analysis detailed in Section 9.2. Assumed cross -over rate of CS group to GA group is 10%.  
Type I error rates are given in Table 2.  
 
Table 1: Power under a neutral prior and cross -over rate of 10%.  
Pr(OR>1)>  N=265  N=260  N=257  N=250  N=245  N=242  N=23 8 N=225  
0.95 0.50 0.49 0.49 0.48 0.47 0.47 0.46 0.44 
0.90 0.66 0.64 0.64 0.64 0.63 0.62 0.62 0.60 
0.85 0.74 0.73 0.73 0.73 0.72 0.72 0.71 0.70 
0.80 0.81 0.80 0.80 0.80 0.79 0.79 0.78 0.77 
0.75 0.85 0.85 0.84 0.85 0.84 0.83 0.83 0.82 
 
 
 
Table 2: Type I error rates under a neutral prior and cross -over rate of 10%.  
Pr(OR>1)>  N=265  N=260  N=257  N=250  N=245  N=242  N=238  N=225  
0.95 0.04 0.04 0.04 0.03 0.04 0.04 0.04 0.04 
0.90 0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.08 
0.85 0.13 0.13 0.13 0.13 0.13 0.13 0.14 0.13 
0.80 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 
0.75 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.24 
 
2. Secondary outcome of dichotomized mRS at 90  days 
 
We assumed good outcome (mRS of 0 -2) rates of 45% for General Anesthesia group and 35% for Conscious Sedati on 
group. We simulated 10,000 trials for each of the sample sizes in Table 3 and calculated power to declare benefit based on 
range of thresholds to declare benefit (i.e., Pr(RR>1)>threshold). For analyses, we used a neutral prior centered at RR of  
1.0 (95 % CI: 0.3 –3.0) for the treatment effect and a log binomial model detailed in section 9.2.  
 
Table 3: Power under a neutral prior and cross -over rate of 10%.  
Pr(RR>1)>  N=265  N=260  N=250  N=242  N=225  
0.95 0.42 0.43 0.42 0.37 0.41 
0.90 0.58 0.57 0.56 0.54 0.56 
0.85 0.67 0.67 0.66 0.62 0.64 
0.80 0.73 0.74 0.73 0.71 0.72 
0.75 0.79 0.79 0.77 0.76 0.77 
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
  
To compute type I error, we assumed equal rates of good outcomes of 35% for both groups. We used the same neutral 
prior (RR of 1.0, 95% CI, 0.3 –3.0) and log binomial model for analysis. Type I error rates are given in Table 4.  
 
Table 4: Type I error rates under a neutral prior and cross -over rate of 10%.  
Pr(RR>1)>  N=265 N=260 N=250 N=242 N=225 
0.95 0.05  0.04  0.04  0.05  0.04  
0.90 0.09  0.09  0.08  0.09  0.08  
0.85 0.14  0.14  0.14  0.15  0.12  
0.80 0.19  0.21  0.19  0.19  0.17  
0.75 0.24  0.25  0.23  0.24  0.24  
 
We also computed the power under a skeptical prior expressing prior belief that Conscious Sedation will have higher rates 
of good outcome. Using a skeptical prior ce ntered at RR of 0.82 (95% CI: 0.27 –2.5) for the analyses gives power shown 
in Table 5. Here, there will be >50% power to convince a skeptic of benefit of General Anesthesia (RR>1) using a 
posterior probability threshold of 90% or  lower.  
 
Table 5: Power und er a skeptical prior and cross -over rate of 10%.  
Pr(RR>1)>  N=265 N=260 N=250 N=242 N=225 
0.95 0.37  0.40  0.37  0.40  0.34  
0.90 0.52  0.56  0.53  0.53  0.50  
0.85 0.62  0.65  0.61  0.63  0.58  
0.80 0.70  0.73  0.70  0.71  0.65  
0.75 0.76  0.78  0.75  0.77  0.71  
age 23 of 31  
IRB NUMBER: HSC -MS-17-0436 
IRB APPROVAL DATE: 02/03/2021  
SEGA Trial Protocol v.1.8  P  
 Appendix  III. Prudent limits of targeted depth and length of ED procedural sedation and analgesia 
according to presedation assessment of aspiration  risk 
 
 
 
